Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Group B Streptococcus alpha-like protein 1 N-terminal domain (Alp1N) is a key surface-anchored protein domain of Streptococcus agalactiae (Group B Streptococcus, or GBS). GBS is a leading cause of neonatal sepsis, meningitis, and pneumonia, as well as adverse pregnancy outcomes like stillbirth and preterm delivery. The Alp1 protein belongs to the alpha-like protein (Alp) family, which are chimeras with a mosaic structure. The N-terminal domain of Alp1 protrudes through the bacterial polysaccharide capsule and is highly immunogenic and functionally active, playing a role in host cell adhesion and invasion by binding to glycosaminoglycans and integrins. Because of its extracellular exposure and conservation across clinical isolates, Alp1N is a major target for vaccine development. MinervaX is developing a recombinant protein-based vaccine candidate, GBS-AlpN (also known as GBS-NN/NN2), which incorporates the N-terminal domains of AlphaC, Rib, Alp1, and Alp2/3 to elicit protective maternal antibodies that cross the placenta and protect newborns.
Active immunization to induce protective maternal IgG antibodies that cross the placenta and mediate opsonophagocytic killing of Group B Streptococcus expressing Alp1
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Group B Streptococcus alpha-like protein 1 N-terminal domain (Alp1N).